Vertigo Treatment Market Research Report Information By Type (BPPV, Labyrinthitis, Vestibular Neuronitis, Meniere’s disease), By Treatment (Anticholinergics, Antihistamines, Benzodiazepines, Others) and By End-User (Hospital, Clinics)-Forecast to 2032

Table of Contents

1. EXECUTIVE SUMMARY

1.1. Market Attractiveness Analysis

1.1.1. Global Vertigo Treatment Market, by Type

1.1.2. Global Vertigo Treatment Market, by Treatment

1.1.3. Global Vertigo Treatment Market, by End User

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.5. Breakdown of Primary Respondents

3.6. Forecasting Techniques

3.7. Research Methodology for Market Size Estimation

3.8. Bottom-Up Approach

3.9. Top-Down Approach

3.10. Data Triangulation

3.11. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.2.1. R&D and Designing

5.2.2. Manufacturing

5.2.3. Distribution & Sales

5.2.4. Post Sales Services

6. GLOBAL VERTIGO TREATMENT MARKET, BY TYPE

6.1. Overview

6.2. Benign paroxysmal positional vertigo (BPPV)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Labyrinthitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Vestibular neuronitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Meniere’s disease

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL VERTIGO TREATMENT MARKET, BY TREATMENT

7.1. Overview

7.2. Anticholinergics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Antihistamines

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Benzodiazepines

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL VERTIGO TREATMENT MARKET, BY END USER

8.1. Overview

8.2. Hospital

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL VERTIGO TREATMENT MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitor Dashboard

10.3. Major Growth Strategy in the Global Vertigo Treatment Market

10.4. Competitive Benchmarking

10.5. The Leading Player in terms of Number of Developments in the Global Vertigo Treatment Market

10.6. Key Developments & Growth Strategies

10.7. Major Players Financial Matrix & Market Ratio

11. COMPANY PROFILES

11.1. F. Hoffmann-La Roche

11.1.1. Company Overview

11.1.2. Drugs/Services Offered

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. GlaxoSmithKline

11.3. Novartis

11.4. Pfizer

11.5. Teva Pharmaceutical

11.6. Sanofi

11.7. AstraZeneca

11.8. Intas Pharmaceutical Ltd

11.9. Sun Pharmaceutical Industries Ltd

11.10. Others

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL VERTIGO TREATMENT MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL VERTIGO TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027(USD MILLION)

TABLE 3 GLOBAL VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 4 GLOBAL VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 5 GLOBAL VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 6 GLOBAL VERTIGO TREATMENT MARKET, BY REGION, 2020-2027(USD MILLION)

TABLE 7 NORTH AMERICA: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 8 NORTH AMERICA: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 9 NORTH AMERICA: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 10 US: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 11 US: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 12 US: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 13 CANADA: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 14 CANADA: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 15 CANADA: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 16 LATIN AMERICA: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 17 LATIN AMERICA: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 18 LATIN AMERICA: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 19 EUROPE: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 20 EUROPE: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 21 EUROPE: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 22 WESTERN EUROPE: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 23 WESTERN EUROPE: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 24 WESTERN EUROPE: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 25 EASTERN EUROPE: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 26 EASTERN EUROPE: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 27 EASTERN EUROPE: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 28 ASIA-PACIFIC: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 29 ASIA-PACIFIC: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 30 ASIA-PACIFIC: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: VERTIGO TREATMENT MARKET, BY TYPE, 2020-2027(USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: VERTIGO TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: VERTIGO TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL VERTIGO TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL VERTIGO TREATMENT MARKET

FIGURE 4 GLOBAL VERTIGO TREATMENT MARKET SHARE, BY TYPE, 2020 (%)

FIGURE 5 GLOBAL VERTIGO TREATMENT MARKET SHARE, BY TREATMENT, 2020 (%)

FIGURE 6 GLOBAL VERTIGO TREATMENT MARKET SHARE, BY END USER, 2020 (%)

FIGURE 7 GLOBAL VERTIGO TREATMENT MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2020 (%)

FIGURE 8 GLOBAL VERTIGO TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 AMERICAS: VERTIGO TREATMENT MARKET SHARE BY REGION, 2020 (%)

FIGURE 10 NORTH AMERICA: VERTIGO TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 EUROPE: VERTIGO TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 12 WESTERN EUROPE: VERTIGO TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 ASIA-PACIFIC: VERTIGO TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 14 MIDDLE EAST & AFRICA: VERTIGO TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 15 GLOBAL VERTIGO TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 16 F. HOFFMANN-LA ROCHE: KEY FINANCIALS

FIGURE 17 F. HOFFMANN-LA ROCHE SEGMENTAL REVENUE

FIGURE 18 F. HOFFMANN-LA ROCHE: REGIONAL REVENUE

FIGURE 19 GLAXOSMITHKLINE: KEY FINANCIALS

FIGURE 20 GLAXOSMITHKLINE: SEGMENTAL REVENUE

FIGURE 21 GLAXOSMITHKLINE: REGIONAL REVENUE

FIGURE 22 NOVARTIS: KEY FINANCIALS

FIGURE 23 NOVARTIS: SEGMENTAL REVENUE

FIGURE 24 NOVARTIS: REGIONAL REVENUE

FIGURE 25 PFIZER: KEY FINANCIALS

FIGURE 26 PFIZER: SEGMENTAL REVENUE

FIGURE 27 PFIZER.: REGIONAL REVENUE

FIGURE 28 TEVA PHARMACEUTICAL: KEY FINANCIALS

FIGURE 29 TEVA PHARMACEUTICAL: SEGMENTAL REVENUE

FIGURE 30 TEVA PHARMACEUTICAL: REGIONAL REVENUE

FIGURE 31 ASTRAZENECA: KEY FINANCIALS

FIGURE 32 ASTRAZENECA: SEGMENTAL REVENUE

FIGURE 33 ASTRAZENECA: REGIONAL REVENUE

FIGURE 34 SANOFI: KEY FINANCIALS

FIGURE 35 SANOFI: SEGMENTAL REVENUE

FIGURE 36 SANOFI: REGIONAL REVENUE

FIGURE 37 SUN PHARMACEUTICAL INDUSTRIES: KEY FINANCIALS

FIGURE 38 SUN PHARMACEUTICAL INDUSTRIES: SEGMENTAL REVENUE

FIGURE 39 SUN PHARMACEUTICAL INDUSTRIES: REGIONAL REVENUE